The Evolving Treatment Landscape for Metastatic Differentiated Thyroid Cancer

about

The Evolving Treatment Landscape for Metastatic Differentiated Thyroid Cancer

Item

http://www.wikidata.org/entity/Q26795503

description

2014 nî lūn-bûn

@nan

2014 թուականին հրատարակուած գիտական յօդուած

@hyw

2014 թվականին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

The Evolving Treatment Landscape for Metastatic Differentiated Thyroid Cancer

@ast

The Evolving Treatment Landscape for Metastatic Differentiated Thyroid Cancer

@en

The Evolving Treatment Landscape for Metastatic Differentiated Thyroid Cancer

@nl

type

Item

label

The Evolving Treatment Landscape for Metastatic Differentiated Thyroid Cancer

@ast

The Evolving Treatment Landscape for Metastatic Differentiated Thyroid Cancer

@en

The Evolving Treatment Landscape for Metastatic Differentiated Thyroid Cancer

@nl

prefLabel

The Evolving Treatment Landscape for Metastatic Differentiated Thyroid Cancer

@ast

The Evolving Treatment Landscape for Metastatic Differentiated Thyroid Cancer

@en

The Evolving Treatment Landscape for Metastatic Differentiated Thyroid Cancer

@nl

P1476

The Evolving Treatment Landscape for Metastatic Differentiated Thyroid Cancer

@en

P2093

Carolyn Grande

http://www.w3.org/2001/XMLSchema#string

Marcia S Brose

http://www.w3.org/2001/XMLSchema#string

P2860

Sorafenib in metastatic thyroid cancer: a systematic review

Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples

Phase II trial of sorafenib in advanced thyroid cancer.

Phase II trial of sorafenib in metastatic thyroid cancer

Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.

Approach to and treatment of differentiated thyroid carcinoma.

Management of sorafenib-related adverse events: a clinician's perspective.

Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients.

P304

461-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.6004/JADPRO.2014.5.6.7

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281554315

http://www.w3.org/2001/XMLSchema#string

P698

26328220

http://www.w3.org/2001/XMLSchema#string

P932

4530117

http://www.w3.org/2001/XMLSchema#string